* CU Women Succeeding Symposium sets record attendance
   
* CU system notifies group of employees about W-2 irregularities
   
* Retirees file suit against newly signed PERA law
   
* Tuition flexibility plan might go to lawmakers this month
   
* Faculty Council budget committee offers guide to approaching cuts
   
* Wellness promotion part of planned improvements to health benefits
   
* CU still top contributor to statewide charity campaign
   
* Five questions for Steven Medema
   
* INVST marks 20th year with gala, workshops
   
* People
   
* Did you know...
   
* Letters to the editor
 
 NEWS FROM THE CU SYSTEM
 
  CU-BOULDER
  Conference on World Affairs returns for 62nd run
 
  UCCS
  School of Public Affairs to provide law enforcement education
 
  UC DENVER
  Pyramid Plus center will promote social emotional development in kids
 
  ANSCHUTZ MEDICAL CAMPUS
  University of Colorado Hospital internal medicine, specialty clinic relocating
 
  CU FOUNDATION
  Biotech Building receives boost from $1 million gift
 
  TECH TRANSFER
  Colorado company licenses CU test to assess chronic liver disease
 
 
   Home
   Newsletter Archive
 
Download Newsleter in PDF
 
Share your thoughts
  LETTERS TO THE EDITOR
Share your opinions

CONTACT US
Send your thoughts and suggestions for the Newsletter

News from the CU system - Tech Transfer

Colorado company licenses CU test to assess chronic liver disease

HepQuant-Dual
HepQuant-Dual
The University of Colorado and HepQuant LLC, a Colorado-based company, have completed a licensing agreement allowing HepQuant to further develop a CU diagnostic technology to assess chronic liver disease.

All major manifestations of chronic liver disease – including cirrhosis, ascites, fibrosis, varices and encephalopathy – are linked to an impairment of the liver's portal circulation. About 15 million to 30 million people in the United States, and at least 500 million worldwide, suffer from these diseases.

The first product to be developed based on the licensed technology, HepQuant-Dual, is a noninvasive, cost-effective test that measures the liver's portal circulation using natural compounds labeled with stable isotopes. The test enables a physician to detect liver disease, measure the severity of the disease and predict risk for future complications.

The test was invented by Gregory Everson, professor and director of hepatology at the University of Colorado School of Medicine.

"This is an exciting advance for monitoring patients and provides physicians with a new tool for evaluating liver disease," Everson said. The company anticipates that clinical trials will begin late this year, with commercial availability by 2013, subject to FDA approval.

HepQuant originally optioned the technology from CU in 2008, when it received a $100,000 seed investment from the University of Colorado Technology Transfer Office to support further commercial development.

"Technology Transfer's proof-of-concept investment program helped HepQuant leverage a grant from the Colorado Office of Economic Development and International Trade and augment Dr. Everson's clinical studies with market and regulatory planning, a critical step toward a sustainable new biomedical enterprise," said Tom Smerdon, director of licensing and new business development at the CU Technology Transfer Office.

Bookmark - Print - Share

 
Previous Tech Transfer Stories

01/20/2010
AgriHouse completes license for CU water management technology

01/13/2010
AmideBio licenses technology from CU

01/06/2009
Business collaboration leads to high ranking for CU-Boulder

12/16/2009
License agreement gives Viral Genetics Inc. right to develop cancer therapies

12/09/2009
Soligenix options CU vaccine technology

12/02/2009
Aurora company licenses CU technology for 3-D heart modeling

09/23/2009
Colorado firm aims to commercialize CU breakthroughs in pain management

09/16/2009
Office reports best year for invention disclosures

09/16/2009
Office invites bioscience faculty to submit grant proposals

09/02/2009
Reading software based on CU technology draws national attention

08/19/2009
CU startup to develop 'biogenerator' for medical devices

08/06/2009
CU startup licenses social networking iPhone app